Drugs / Syntropin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00489294 | Aug 2004 → Jun 2005 | pituitary deficiency | Phage Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Syntropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00489294 ↗ |
| Modality | Protein / enzyme biologic | “Syntropin (a human growth hormone)” NCT00489294 ↗ |
| Route | Subcutaneous | “Syntropin will be administered by subcutaneous injection.” NCT00489294 ↗ |